As a triple incretin receptor agonist, it: Activates GLP-1 receptors , reducing appetite, slowing gastric emptying, and improving insulin secretion Activates GIP receptors , enhancing insulin response and potentially supporting fat metabolism Activates glucagon receptors , increasing energy expenditure and hepatic glucose output Whilst glucagon receptor activation increases hepatic glucose output, the net glycaemic effect of retatrutide is mitigated by the concurrent GLP-1 and GIP activity, resulting in overall improvements in glycaemic control in trial participants
The specific packages used included tidyverse (v2.0.0), survival (v3.8-3), MatchIt (v4.7.2), survminer (v0.5.0), cmprsk (v3.1), WeightIt (v1.2.0) and mediation (v4.5.0)
Inflammation: Roles in Skeletal Muscle Atrophy
Understanding how long peptides take to work across different categories provides a realistic framework for setting expectations during the escalation phase